Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
PreDxion Bio developed a rapid, multiplexed microfluidic/nanosensor diagnostic platform capable of quantifying multiple serum cytokines from small blood samples at the bedside. The company also pivoted to develop a scalable saliva-based antigen test for SARS-CoV‑2 during the pandemic. Their technology received FDA Breakthrough Device designation and was used in partnerships with pharmaceutical companies to monitor immune response after CAR-T cell therapies and predict complications such as cytokine release syndrome.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on PreDxion Bio.